Broome Oncology
Latest Clinical News

Keytruda plus Lenvima Approved for Certain Patients with Uterine Cancer (09-19-2019)

The United States Food and Drug Administration (FDA) granted accelerated approval to the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability... Continue Reading

Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia (09-3-2019)

Flumatinib may be more effective than Gleevec (imatinib) for initial treatment of chronic phase-chronic myeloid leukemia (CML-CP) according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Chronic... Continue Reading

Isatuximab in Multiple Myeloma (08-27-2019)

The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to randomized phase 3 study results presented at ASCO Annual... Continue Reading

Lynparza-Avastin Maintenance Delays Progression of Ovarian Cancer (08-20-2019)

Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza (olaparib) plus Avastin (bevacizumab) compared to Avastin alone in women with or without BRCA gene mutations have been... Continue Reading

FDA Orders Allergan to Recall Textured Breast Implants Over Cancer Risk (08-19-2019)

The U.S. Food and Drug Administration (FDA) has requested that Allergan recall its BIOCELL textured breast implants due to a risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), according to an announcement from the agency. “Although... Continue Reading

Inherited pancreatic cancer risk mutation identified (08-15-2019)

Scientists have found a rare, inherited gene mutation that raises the risk of pancreatic cancer and other malignancies In the future, individuals with a strong family history of pancreatic cancer could be tested to determine if they carry the mutation. Scientists... Continue Reading

Vaccine for Acute Myeloid Leukemia? (08-14-2019)

A personalized cancer vaccine markedly improved outcomes for patients suffering from acute myeloid leukemia (AML), a potentially lethal blood cancer, in a clinical trial led by investigators at Beth Israel Deaconess Medical Center (BIDMC). The product... Continue Reading

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer (08-1-2019)

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer On July 30, 2019, the Food and Drug Administration approved darolutamide (NUBEQA, Bayer HealthCare Pharmaceuticals Inc.) for non-metastatic castration-resistant prostate... Continue Reading

Dana-Farber Opens New Clinical Trials for Patients with Endometrial Cancer (07-30-2019)

A recent dearth of clinical trials of treatments for endometrial cancer has segued into a research revival – including four new trials led by Dana-Farber investigators – spurred by advances in the scientific understanding of the disease. The trials... Continue Reading

FDA Approves Ruxience Biosimlar to Rituxan (07-25-2019)

The FDA approved rituximab-pvvr, a rituximab biosimilar, for use alone or in combination with chemotherapy for the treatment of adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as granulomatosis... Continue Reading

FDA grants breakthrough therapy designation to Keytruda-Lenvima combination for hepatocellular carcinoma (07-24-2019)

The FDA granted breakthrough therapy designation to pembrolizumab in combination with lenvatinib as first-line treatment for patients with advanced unresectable hepatocellular carcinoma who are not able to receive locoregional treatment. This is the third... Continue Reading

Bladder Cancer Advocacy Network Announces 2019 Bladder Cancer Research Innovation Awardee (07-17-2019)

(July 8, 2019, Bethesda, MD) Today, the Bladder Cancer Advocacy Network (BCAN) announced the recipient of its prestigious Bladder Cancer Research Innovation Award. This year’s awardee is Philip Beachy, Ph.D., Professor of Urology and of Developmental... Continue Reading

Next Page »